ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 30, 2009-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the months of December 2009 and January 2010.

• The J.P. Morgan SMid Cap Conference 2009
  New York, NY.
  December 3, 2009
  Presentation Time: 2:15 PM Eastern
• The J.P. Morgan 28^th Annual Healthcare Conference 2010
  San Francisco, CA.
  January 11, 2010
  Presentation Time: 4:30 PM Pacific

During each presentation, a member of the company’s senior management team will provide a corporate overview, including a discussion of product development programs, corporate activities and financial performance.

A webcast of these presentations will be available both live and by replay, accessible from the company’s website www.emergentbiosolutions.com under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Source: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
Media:
Tracey Schmitt, Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com